These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26205674)

  • 1. Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure.
    Chang J; Guo JT
    Antiviral Res; 2015 Sep; 121():152-9. PubMed ID: 26205674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.
    Zhang E; Kosinska A; Lu M; Yan H; Roggendorf M
    Antiviral Res; 2015 Nov; 123():193-203. PubMed ID: 26476376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING agonists induce an innate antiviral immune response against hepatitis B virus.
    Guo F; Han Y; Zhao X; Wang J; Liu F; Xu C; Wei L; Jiang JD; Block TM; Guo JT; Chang J
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1273-81. PubMed ID: 25512416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Pattern Recognition Receptor Ligands on Induction of Innate Immunity and Control of Hepatitis B Virus Infection.
    Asadi-Asadabad S; Sarvnaz H; Amiri MM; Mobini M; Khoshnoodi J; Hojjat-Farsangi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Shokri F
    Viral Immunol; 2021 Oct; 34(8):531-541. PubMed ID: 34030480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
    Guo JT; Guo H
    Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.
    Chang J; Block TM; Guo JT
    Antiviral Res; 2012 Dec; 96(3):405-13. PubMed ID: 23072881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis B: A wave of new therapies on the horizon.
    Block TM; Rawat S; Brosgart CL
    Antiviral Res; 2015 Sep; 121():69-81. PubMed ID: 26112647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus: new therapeutic perspectives.
    Lin CL; Yang HC; Kao JH
    Liver Int; 2016 Jan; 36 Suppl 1():85-92. PubMed ID: 26725903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral administered particulate yeast-derived glucan promotes hepatitis B virus clearance in a hydrodynamic injection mouse model.
    Yu X; Zhang D; Shi B; Ren G; Peng X; Fang Z; Kozlowski M; Zhou X; Zhang X; Wu M; Wang C; Yuan Z
    PLoS One; 2015; 10(4):e0123559. PubMed ID: 25856080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies.
    Isorce N; Lucifora J; Zoulim F; Durantel D
    Antiviral Res; 2015 Oct; 122():69-81. PubMed ID: 26275801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells.
    Guo H; Jiang D; Ma D; Chang J; Dougherty AM; Cuconati A; Block TM; Guo JT
    J Virol; 2009 Jan; 83(2):847-58. PubMed ID: 18971270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.
    Suslov A; Wieland S; Menne S
    Curr Opin Virol; 2018 Jun; 30():9-17. PubMed ID: 29444493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man.
    Mozer-Lisewska I; Sikora J; Kowala-Piaskowska A; Kaczmarek M; Dworacki G; Zeromski J
    Arch Immunol Ther Exp (Warsz); 2010 Aug; 58(4):295-302. PubMed ID: 20533094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients.
    Lu HY; Zhuang LW; Yu YY; Si CW
    J Viral Hepat; 2010 Mar; 17 Suppl 1():59-65. PubMed ID: 20586935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview.
    Kayesh MEH; Kohara M; Tsukiyama-Kohara K
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
    Wang FS; Zhang Z
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):499-512. PubMed ID: 19817672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.
    Lan P; Zhang C; Han Q; Zhang J; Tian Z
    Hepatology; 2013 Jul; 58(1):73-85. PubMed ID: 23447417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
    Nassal M
    Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.